BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (BCLI) is scheduled to report Q2 earnings on August 6, 2026.
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. has beaten EPS estimates in 4 consecutive quarters.
Over the last 4 quarters, BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. has averaged an EPS surprise of 0.39% and a revenue surprise of 0.00%.
Analyze the earnings history of BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. using advanced sorting and filters.
The chart below shows BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc.'s reported EPS compared to analyst estimates over recent quarters.
The chart below shows BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc.'s reported revenue compared to analyst estimates over recent quarters.
BRAINSTORM CELL THERAPUTC by BrainStorm Cell Therapeutics Inc. (BCLI) is scheduled to report earnings on August 6, 2026. The last reported earnings were for reported on May 15, 2026 for Q1.
The Actual EPS was $-0.19, which missed the estimate of $0.00.
The Actual Revenue was $0.00, which hit the estimate of $0.00.
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2026-03-31 | $-0.20 | $-0.39 | 48.7 % |
| Q3 | 2025-11-14 | $-0.19 | $-0.37 | 48.6 % |
| Q2 | 2025-08-14 | $-0.34 | $-0.36 | 5.56 % |
| Q1 | 2025-05-15 | $-0.45 | $-0.97 | 53.6 % |